Trials / Suspended
SuspendedNCT04906369
Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring
Optimizing Treatment of Metastatic Breast Cancer Through Real-Time Disease Monitoring
- Status
- Suspended
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates if blood tests can detect changes in disease status during treatment for stage IV breast cancer. Information from this study may help researchers learn more about metastatic breast cancer and how to optimize treatment.
Detailed description
PRIMARY OBJECTIVES: I. To identify subtype-specific signatures for breast cancer using genomic positioning of plasma deoxyribonucleic acid (DNA) fragments. II. To validate changes in circulating tumor-derived DNA (ctDNA) levels as a biomarker for treatment monitoring in patients with metastatic breast cancer. OUTLINE: Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biospecimen Collection | Undergo collection of blood samples |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
- First posted
- 2021-05-28
- Last updated
- 2025-05-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04906369. Inclusion in this directory is not an endorsement.